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of thrombolysis after endovascular aneurysm repair
Jessica Belchos, MSc,a Mark Wheatcroft, MD, FRCS,a,b Vikramaditya Prabhudesai, MBBS, MS, FRCR,b,c
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Endoleaks, deﬁned as blood ﬂow outside the graft but inside the aneurysm sac, are a common complication after
endovascular aneurysm repair. Sometimes however, for reasons not fully understood, expansion of the aneurysm sac can
occur with no identiﬁable endoleak, a phenomenon termed endotension, or a type V endoleak. We describe a case of
endotension in a 71-year-old man that developed after recurrent stent graft thrombosis requiring thrombolysis 3 years
after the initial endovascular implantation. To our knowledge, this is the ﬁrst description in the literature of endotension
after multiple rounds of thrombolytic treatment. (J Vasc Surg Cases 2015;1:24-7.)The goal of endovascular aneurysm repair (EVAR) is
exclusion of the aneurysm sac, which, if successful, may
result in evidence of the aneurysm sac shrinking on
follow-up imaging.1 Although EVAR has many beneﬁts
over open surgery, it also has its own speciﬁc potential
complications. If aneurysm sac expansion occurs postoper-
atively, it is usually due to the development of an endoleak,
deﬁned as blood ﬂow outside the graft into the aneurysm
sac.2-4 Endoleaks are one of the commonest complications
after EVAR.5 The culprit blood ﬂow can usually be seen on
imaging, and the endoleak is appropriately classiﬁed: type I
involves proximal or distal seal zones, type II involves pat-
ent branch vessels, type III refers to component junction or
fabric failure, and type IV refers to fabric porosity; ﬁnally,
persistent sac growth with no identiﬁable leak is termed
type V endoleak or endotension.1-6 The etiology of endo-
tension is still a topic of debate, but there are several the-
ories of its pathogenesis.7,8
Another complication of EVAR is stent graft throm-
bosis, often resulting in emergency presentation with acute
limb ischemia. In the absence of any absolute contraindica-
tions, graft thrombosis can often be successfully treated by
the use of thrombolytic agents, such as recombinant tissue
plasminogen activating factor (r-tPA).9 Thrombolytics
create a generalized lytic state, such that target throm-
boemboli and protective hemostatic thrombi are both
broken down, resulting in restoration of luminal patency
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In this case study, we present an example of the devel-
opment of endotension preceded and thus potentially
caused by repeated treatment of stent graft thrombosis
with thrombolysis, 3 years after EVAR. The patient was
notiﬁed of this interesting case and consented to
publication.
CASE REPORT
In 2011, a 69-year-old man underwent elective EVAR with a
Cook Flex bifurcated graft (Cook Medical, Bloomington, Ind) for
a 5.9-cm infrarenal abdominal aortic aneurysm (AAA) and made
an uneventful recovery (Fig 1, a). A postoperative computed to-
mography angiogram (CTA) at 6 weeks showed good position
of the graft, with no endoleaks or graft kinks (Fig 1, b). A duplex
ultrasound scan at the 6-month follow-up a showed appropriate
reduction of the AAA to 5.4 cm, with no observable endoleaks
or limb narrowing.
The patient presented 8 months after implant with an acutely
ischemic right lower limb. He had severe pain in the right leg with
acute deterioration in function, and an examination found no
palpable femoral pulse. A subsequent CTA showed thrombosis
of the right limb of the graft and common iliac artery, with no iliac
limb kinks (Fig 2, a).
He received successful catheter-directed thrombolysis with rt-
PA consisting of a 10-mg bolus, followed by a continuous infusion
of 1 mg/h for 16 hours, which led to complete resolution of the
thrombus on angiogram. Reconstruction and subsequent analysis
of his CTA revealed no limb kinks or any other mechanical reason
for limb occlusion. Despite a comprehensive hematologic workup,
no etiology was identiﬁed, and he was discharged with warfarin
therapy.
The patient presented again 17 months after the initial
implant, complaining of a 2-week history of worsening exertional
right buttock and lower limb pain, consistent with new intermit-
tent claudication but also associated with numbness and pares-
thesia in the lower limb. On examination, he had a palpable but
Fig 1. a, Completion angiogram at the time of endograft implantation. b, The postoperative axial computed
tomography angiography (CTA) displays shrinkage of the aneurysm sac to 5.4 cm.
Fig 2. a, Computed tomography angiography (CTA) axial image shows occlusive thrombus in the right limb (arrow).
b, Completion angiogram after the second treatment with thrombolysis shows patent graft limbs.
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which were previously present.
A CTA showed recurrent occlusion of the right limb of the
graft, with no graft displacement or kink. Of note, his anticoagu-
lation therapy had been subtherapeutic for the previous 2 to
4 weeks. He again received thrombolysis via right common
femoral access with 10-mg bolus of r-tPA, followed by 1 mg/h
for 18 hours (Fig 2, b).
Acute abdominal pain developed after this procedure. A
further CTA showed complete resolution of the thrombus and pat-
ent graft and vessels, but with a large increase in the AAA diameterfrom 5.4 cm to 6.6 cm, with evidence of retroperitoneal stranding
but no frank hematoma. This raised the possibility of acute endo-
tension (Fig 3, a). He was closely monitored, and a repeat CT scan
72 hours later showed some shrinkage of the aneurysm sac to
6.4 cm, with resolution of the previous retroperitoneal ﬁndings
likely secondary to cessation of thrombolysis.
Because the patient’s symptoms resolved and he remained he-
modynamically stable, he was continued on conservative manage-
ment and was discharged once his international normalized ratio
was within the therapeutic range. Follow-up with duplex ultra-
sound imaging 6 weeks later showed a widely patent graft with a
Fig 3. a, Computed tomography angiography (CTA) shows a marked increase in aneurysm diameter (6.6 cm), with
evidence of blood stranding in the retroperitoneum after treatment with thrombolytics. b, Subsequent follow-up
duplex ultrasound scan at 29 months after the initial endovascular aneurysm repair (EVAR) implantation of the
endograft.
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duplex assessment at 29 months showed a sac size of 4.6 cm
with no endoleak (Fig 3, b).
DISCUSSION
The goal of EVAR is to successfully repair an AAA and
thus prevent death due to rupture.3 However, complica-
tions from EVAR, such as endoleak, may occur, and if
persistent can cause AAA expansion with resultant
rupture.4,7,8,10 This also applies to endotension, the least
understood of all endoleaks. Our patient demonstrated
this complication after the need for multiple rounds of
thrombolysis. To our knowledge, no cases of the develop-
ment of endotension after thrombolysis treatment are
documented in the literature.
As stated previously, the pathophysiology underlying
the development of endotension remains unclear. The
three main theories are:
d Direct pressure transmission from the aortic lumen due
to thrombus formation or undetected endoleak;
d Porosity of the graft causing microleaks and transuda-
tion; and
d Pressure build up from accumulation of sac contents
such as thrombus ﬁbrinolysis/hygroma and enzymatic
degradation.7,8
The endotension in our patient can be supported by a
combination of the latter two theories. Endotension gener-
ally manifests as delayed aneurysm expansion after EVAR,
and the case described here appears to be related to the
use of thrombolysis. Despite extensive imaging studies,
no endoleaks were found to account for enlarging sac
size. In one case study, four patients presented with endo-
tension after EVAR with clear, highly viscous ﬂuid in the
aneurysm sac but no bleeding, which led to the diagnosis
of aneurysm sac hygroma and endotension.1 Analysis of
sac contents revealed prominent local active hyperﬁbrinol-
ysis and coagulation factors. The authors postulated that
local active factors may cause rebleeding, liquefaction,
and continued sac expansion.We propose that the presence of thrombolytic agents in
the area of the graft may have contributed to an increased
porosity of the graft, which allowed increased transudation
into the aneurysm sac and thus sac expansion with no iden-
tiﬁable endoleak. Because the patient’s symptoms resolved
after the second round of thrombolysis, no treatment for
endotension/sac expansion was performed.
Because the cause of endotension is not yet clear, man-
agement is highly variable.7,10 A sac that reduces in size af-
ter initial enlargement is considered free of endotension,
and conservative treatment may be most appropriate.4
Although some studies suggest open conversion surgery,4,6
others suggest conservative management is generally
appropriate, assuming the patient is asymptomatic and
the sac size is stable.5,7,10,11 Therefore, until more is known
about the natural history and management of endotension,
rigorous surveillance is important in these patients.4,6,8
CONCLUSIONS
The pathogenesis and natural history of endotension
are not yet clearly deﬁned. Recurrent rounds of thrombo-
lytic therapy after EVAR may lead to the development of
endotension. Conservative management may be most
appropriate in asymptomatic patients; however, close sur-
veillance is essential to monitor the patient for rupture
and other complications that may require further
intervention.REFERENCES
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